Informatie:
Fout:
ID
34140
Beschrijving
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention; ODM derived from: https://clinicaltrials.gov/show/NCT02334254
Link
https://clinicaltrials.gov/show/NCT02334254
Trefwoorden
Versies (1)
- 14-01-19 14-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
14 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Atrial Fibrillation NCT02334254
Eligibility Atrial Fibrillation NCT02334254
- StudyEvent: Eligibility
Similar models
Eligibility Atrial Fibrillation NCT02334254
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
a long-term indication for oral anticoagulation treatment (until at least 1 year after the study)
boolean
ID.2
Item
a severe coronary lesion (at least 75% stenosis on angiography or fractional flow reserve lower than 0•80) with indication for pci
boolean
ID.3
Item
age 18-80 years
boolean
ID.4
Item
history of intracranial bleeding;
boolean
ID.5
Item
cardiogenic shock;
boolean
ID.6
Item
contra indication to use of antiplatelet or anticoagulation drugs;
boolean
ID.7
Item
peptic ulcer in the previous 6 months;
boolean
ID.8
Item
thrombo cytopenia (platelet concentration lower than 50~10⁹/l);
boolean
ID.9
Item
major bleeding (according to the thrombolysis in myocardial infarction [timi] criteria) in the past 12 months; and
boolean
ID.10
Item
pregnancy.
boolean